StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Free Report) in a research note issued to investors on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00. The company has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61.
Genocea Biosciences Company Profile
Further Reading
- Five stocks we like better than Genocea Biosciences
- What is a buyback in stocks? A comprehensive guide for investors
- Comprehensive Analysis of PayPal Stock
- Best Stocks Under $10.00
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- Roth IRA Calculator: Calculate Your Potential Returns
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.